Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis.

Date publication

novembre 2025

Journal

Multiple sclerosis and related disorders

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Hauser SL, Freedman MS, Nakahara J, Paling D, de Seze J, Li J, Abeyewickreme A, Wu M, Sullivan R, Pardo G, Montalban X, Wiendl H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41380509

Résumé

We report ofatumumab's longer-term safety and efficacy in recently diagnosed (≤3 years) treatment-naive (RDTN) people living with relapsing multiple sclerosis (plwRMS).

Mots clés

ALITHIOS, Long-term efficacy, Long-term safety, Ofatumumab, Relapsing multiple sclerosis

Référence

Mult Scler Relat Disord. 2025 11 25;105:106886